SKB BIO (06990) and Merck's collaborative Phase III study of TROP2 ADC in gastroesophageal adenocarcinoma meets primary endpoint

date
20:33 20/11/2026
avatar
GMT Eight
Kelun-Biotech and Merck's collaboratively developed TROP2-targeted antibody-drug conjugate (ADC) sac-TMT met the primary overall survival (OS) endpoint in the pivotal Phase III TroFuse-015 study, becoming the world's first TROP2 ADC to improve OS compared with physician's choice (TPC) in patients with advanced gastroesophageal adenocarcinoma in a global Phase III study. The study's secondary PFS endpoint was not met, ORR showed only numerical improvement without formal testing, and the safety profile was consistent with previous findings.
SKB BIO (06990) and Merck & Co., Inc. (MRK.US) announced that their jointly developed investigational TROP2-targeting antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) met the primary endpoint of overall survival (OS) in the pivotal Phase III TroFuse-015 study. sac-TMT is the first TROP2 ADC globally to improve OS compared with physician's choice (TPC) in a global Phase III study in patients with advanced gastroesophageal adenocarcinoma who had previously received two or more lines of systemic therapy. The TroFuse-015 study evaluated sac-TMT for the treatment of locally advanced unresectable or metastatic gastroesophageal adenocarcinoma, with the comparator TPC regimen including trifluridine/tipiracil, irinotecan, paclitaxel, or docetaxel. This is the first time a TROP2 ADC has demonstrated an OS benefit in a global Phase III trial in this patient population, where there is significant unmet need. The data will be presented at an upcoming medical conference and shared with regulatory authorities. The final analysis showed that sac-TMT achieved a statistically significant and clinically meaningful improvement in OS compared with TPC in the aforementioned patients who had previously received two or more lines of systemic therapy. Results were generally consistent across subgroups regardless of TROP2 expression status. sac-TMT did not meet the secondary endpoint of progression-free survival (PFS) by blinded independent central review (BICR). In addition, the secondary endpoint of objective response rate (ORR) showed a numerical improvement favoring sac-TMT but was not formally tested per the prespecified analysis plan. The safety profile was consistent with previously reported sac-TMT studies, with no new safety signals observed. Dr. Marjorie Green, Senior Vice President and Head of Global Clinical Development, Oncology, at Merck & Co., Inc. Research Laboratories, said: "sac-TMT is the first TROP2 ADC to improve OS compared with TPC in a global Phase III study in advanced gastroesophageal adenocarcinoma, demonstrating its potential in this particularly challenging disease setting. There is a substantial unmet need among these patients for therapies that can improve survival. We look forward to discussing these data with regulatory authorities and sharing them with the scientific community on behalf of patients who may benefit." TroFuse-015 is also the second positive Phase III study from Merck & Co., Inc.'s sac-TMT TroFuse clinical development program. The program currently includes 18 ongoing global Phase III trials, covering a broader range of diseases and treatment settings than any TROP2-targeting ADC to date. The program is evaluating sac-TMT across multiple tumor types including endometrial cancer, bladder cancer, breast cancer, cervical cancer, gastric cancer, non-small cell lung cancer, and ovarian cancer, spanning from early to late-stage disease, both as monotherapy and in combination with immunotherapy. Of the 18 Phase III studies in the program, 14 are exploring first-in-class opportunities to address unmet medical needs, including TroFuse-015. Public information shows that Kelun-Biotech, as the innovative drug platform within the Kelun system, has accumulated over a decade of ADC R&D experience and is the first Chinese company to establish an ADC collaboration with a top-10 multinational pharmaceutical company. sac-TMT (lukangshaduo monoclonal antibody, trade name JIATAILAI) is the company's core asset and the world's first TROP2 ADC approved for marketing in lung cancer indications. It has currently been approved for 4 indications in China, covering triple-negative breast cancer, EGFR-mutant non-small cell lung cancer, and HR+/HER2- breast cancer, of which the first 2 have been included in medical insurance; the drug has also received 6 breakthrough therapy designations from the National Medical Products Administration. The overseas rights to sac-TMT originate from a licensing agreement in May 2022. At that time, Kelun-Biotech exclusively granted Merck & Co., Inc. the rights to develop, use, manufacture, and commercialize the drug (SKB264, Merck & Co., Inc. designation MK-2870) outside Greater China, and received non-refundable payments of US$17 million and US$30 million upon the agreement's effectiveness and after the signing of amendments, respectively, with cumulative milestone payments not exceeding US$1.363 billion, plus tiered royalties on net sales. Since then, the two parties have successively reached licensing agreements for SKB315 and 7 preclinical ADC assets, with total upfront and milestone payments for transactions since May 2022 potentially exceeding US$11.8 billion. Currently, all overseas clinical studies of sac-TMT are sponsored and led by Merck & Co., Inc.